As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate

Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.